{"id":"NCT02337725","sponsor":"Takeda","briefTitle":"A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-07","primaryCompletion":"2016-09-15","completion":"2016-09-15","firstPosted":"2015-01-14","resultsPosted":"2018-12-31","lastUpdate":"2022-03-02"},"enrollment":244,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"TVP-1012","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TVP-1012 1 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.","primaryOutcome":{"measure":"Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III Total Score","timeFrame":"From Baseline to Week 26 (LOCF)","effectByArm":[{"arm":"Placebo","deltaMin":1.87,"sd":0.752},{"arm":"TVP-1012 1mg","deltaMin":-4.52,"sd":0.784}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":29},"locations":{"siteCount":55,"countries":["Japan"]},"refs":{"pmids":["30205936"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":126},"commonTop":["Nasopharyngitis","Fall"]}}